Skip to main content

Advertisement

Table 2 Proportion of 2010-UA and 1987-UA patients progressing to RA within 1 year within groups of similar ACPA and RF status

From: Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example

  RA No RA % RA/% non-RA development (pre-test risks)a OR (95% CI) PPV (95% CI) NPV (95% CI)
1987-UA patients (n = 1352)
 ACPA–RF– (n = 929) anti-CarP+ 23 42 21/79 2.1 (1.3–3.7) 35 (25–48) 80 (77–82)
anti-CarP– 176 688
 ACPA+RF– (n = 64) anti-CarP+ 16 10 50/50 2.2 (0.8–6.1) 62 (43–78) 58 (42–72)
anti-CarP– 16 22
 ACPA–RF+ (n = 140) anti-CarP+ 8 9 39/61 1.4 (0.5–4.0) 47 (26–69) 62 (53–70)
anti-CarP– 47 76
 ACPA+RF+ (n = 219) anti-CarP+ 107 42 71/29 1.2 (0.6–2.2) 72 (64–78) 31 (22–43)
anti-CarP– 48 22
2010-UA patients (n = 838)
 ACPA–RF– (n = 755) anti-CarP+ 1 48 4/96 0.5 (0.1–3.5) 2 (0–11) 96 (94–97)
anti-CarP– 30 676
 ACPA+RF– (n = 15) anti-CarP+ 1 2 13/87 5.5 (0.2–129) 33 (6–79) 92 (65–99)
anti-CarP– 1 11
 ACPA–RF+ (n = 35) anti-CarP+ 0 4 17/83 Undefined 0 (0–49) 81 (64–91)
anti-CarP– 6 25
 ACPA+RF+ (n = 33) anti-CarP+ 9 12 42/58 1.1 (0.2–4.4) 43 (24–63) 58 (32–81)
anti-CarP– 5 7
  1. Patients were stratified according to the presence of different autoantibody combinations (ACPA–RF–, ACPA+RF–, ACPA–RF+, and ACPA+RF+); within these groups the predictive value of the presence of anticarbamylated protein (anti-CarP) antibodies for progression to rheumatoid arthritis (RA) was determined, both within 2010-undifferentiated arthritis (UA) and 1987-UA patients
  2. ACPA, anticitrullinated protein antibodies; CI, confidence interval; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; RF, rheumatoid factor
  3. a Observed risk of RA development within ACPA and RF strata (pre-test risks), without information on anti-CarP status